CytoDyn Inc.

CYDYSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1175680

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$266.0K	$0.00	—
Gross Profit	—	—	$213.0K	$213.0K	—
Research and Development Expense	—	$2.6M	$27.0M	$52.6M	$42.5M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$18.1M	-$40.6M	-$145.4M	-$74.6M	-$55.9M
Interest Expense	—	—	—	—	—
Other Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$11.1M	$11.3M	$29.2M	$132.1M	$50.5M
Assets, Current	$10.8M	$10.8M	$10.5M	$36.1M	$36.8M
Cash and Cash Equivalents, at Carrying Value	$3.1M	$2.5M	$4.2M	$14.3M	$2.6M
Inventory, Net	—	$0.00	—	—	$19.1M
Liabilities	$127.9M	$120.8M	$123.6M	$153.1M	$53.0M
Liabilities, Current	$84.2M	$119.8M	$123.2M	$152.5M	$44.5M
Long-term Debt	$45.0M	$45.7M	$42.2M	$64.8M	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$11.0M	-$25.1M	-$77.7M	-$68.8M	-$50.5M
Net Cash Provided by (Used in) Investing Activities	—	—	—	-$41.0K	-$45.0K
Net Cash Provided by (Used in) Financing Activities	$11.7M	$29.9M	$48.0M	$79.7M	$52.7M
Payments to Acquire Property, Plant, and Equipment	—	—	—	$41.0K	$26.0K
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)